BioVaxys is a clinical-stage biopharmaceutical company focused on out-licensing immunotherapy assets developed from its proprietary DPX? platform. The DPX platform has demonstrated safety, tolerability, and efficacy in multiple Phase 1 and Phase 2B clinical studies across oncology, infectious disease, allergy, and autoimmune disorders.
